Inspire Medical SystemsINSP
INSP
About: Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
Employees: 1,011
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
400% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 5 (+4) [Q3]
63% more capital invested
Capital invested by funds: $4.27B [Q2] → $6.96B (+$2.7B) [Q3]
32% more first-time investments, than exits
New positions opened: 79 | Existing positions closed: 60
6% more funds holding
Funds holding: 322 [Q2] → 341 (+19) [Q3]
3.47% more ownership
Funds ownership: 107.27% [Q2] → 110.74% (+3.47%) [Q3]
3% more repeat investments, than reductions
Existing positions increased: 113 | Existing positions reduced: 110
8% less call options, than puts
Call options by funds: $121M | Put options by funds: $131M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$198
5%
upside
Avg. target
$238
26%
upside
High target
$260
38%
upside
7 analyst ratings
5 positive
71%
2 neutral
29%
0 negative
0%
B of A Securities Bob Hopkins 50% 1-year accuracy 1 / 2 met price target | 35%upside $255 | Buy Upgraded | 20 Nov 2024 |
RBC Capital Shagun Singh 53% 1-year accuracy 41 / 78 met price target | 38%upside $260 | Outperform Reiterated | 5 Nov 2024 |
Piper Sandler Adam Maeder 63% 1-year accuracy 10 / 16 met price target | 38%upside $260 | Overweight Reiterated | 5 Nov 2024 |
Stifel Jonathan Block 6% 1-year accuracy 1 / 18 met price target | 6%upside $200 | Hold Reiterated | 5 Nov 2024 |
Wells Fargo Larry Biegelsen 51% 1-year accuracy 24 / 47 met price target | 5%upside $198 | Equal-Weight Maintained | 5 Nov 2024 |
Financial journalist opinion
Based on 4 articles about INSP published over the past 30 days
Negative
Investopedia
3 days ago
Sleep Apnea Device Maker Stocks Slide on FDA Ruling for Eli Lilly's Zepbound
Shares of ResMed (RMD) and Inspire Medical Systems (INSP) fell Monday as the companies behind products to treat sleep apnea faced a new threat from weight-loss drugs.
Neutral
Business Wire
3 weeks ago
Presidio Medical™ Announces Appointment of Richard J. Buchholz to Join its Board of Directors
SAN MATEO, Calif.--(BUSINESS WIRE)-- #backpain--Presidio Medical, Inc., a clinical stage company developing a transformational neuromodulation platform, is pleased to announce Richard J. Buchholz will join its Board of Directors. Rick is the Chief Financial Officer of Inspire Medical Systems, Inc. (NYSE: INSP), where he has played a pivotal role in driving strategic financial and operational growth for the global leader in the development and commercialization of innovative, minimally invasive solutions fo.
Positive
Zacks Investment Research
3 weeks ago
5 Growth Stocks to Buy in December for Impressive Short-Term Upside
These five growth stocks have strong potential for December. These are: MNDY, PSN, PI, INSP, INGR.
Positive
Zacks Investment Research
3 weeks ago
5 Medical Info System Stocks to Buy for a Stable Portfolio in 2025
Five medical info systems stocks have strong potential for 2025. These are: INSP, OMCL, TALK, BFLY, CLOV.
Positive
Benzinga
1 month ago
Inspire Medical's Strong 2025 Outlook And Upcoming Inspire V Launch Earns Analyst Upgrade
BofA Securities has upgraded Inspire Medical Systems, Inc. INSP and says the company now falls in the profitable growth category.
Neutral
GlobeNewsWire
1 month ago
UPDATED – Inspire Medical Systems, Inc. to Present at Jefferies London Healthcare Conference
MINNEAPOLIS, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024.
Neutral
GlobeNewsWire
1 month ago
Inspire Medical Systems, Inc. Announces $75 million Accelerated Share Repurchase Program
MINNEAPOLIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire,” or the “Company”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced that it entered into an accelerated share repurchase (“ASR”) transaction under an agreement with Goldman Sachs & Co. LLC, to repurchase an aggregate of $75.0 million of shares of the Company's common stock, par value $0.001 per share. The ASR transaction is being completed pursuant to a previously announced $150.0 million share repurchase program authorized by the Company's Board of Directors.
Neutral
GlobeNewsWire
1 month ago
Inspire Medical Systems, Inc. to Present at Jefferies London Healthcare Conference
MINNEAPOLIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024.
Positive
Zacks Investment Research
1 month ago
INSP Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts
Inspire Medical's both geographic segments witness strong revenue growth on the back of solid product demand in the third quarter.
Neutral
Seeking Alpha
1 month ago
Inspire Medical Systems, Inc. (INSP) Q3 2024 Earnings Call Transcript
Inspire Medical Systems, Inc. (NYSE:INSP ) Q3 2024 Earnings Conference Call November 4, 2024 5:00 PM ET Company Participants Ezgi Yagci – Vice President-Investor Relations Tim Herbert – President and Chief Executive Officer Rick Buchholz – Chief Financial Officer Conference Call Participants Robbie Marcus – JPMorgan Danielle Antalffy – UBS Travis Steed – Bank of America Securities Adam Maeder – Piper Sandler David Rescott – Baird Michael Sarcone – Jefferies Richard Newitter – Truist Securities Larry Biegelsen – Wells Fargo Shagun Singh – RBC Kallum Titchmarsh – Morgan Stanley Jon Block – Stifel Anthony Petrone – Mizuho Americas Brett Fishbin – KeyBanc Capital Markets Chris Pasquale – Nephron Research Michael Polark – Wolfe Research Mike Kratky – Leerink Partners Suraj Kalia – Oppenheimer & Co Operator Good afternoon. My name is Dilem, and I'll be your conference operator today.
Charts implemented using Lightweight Charts™